Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Maribavir safety under review for kidney patients with CMV

NCT ID NCT06243731

Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study reviews medical records of 10 adult transplant patients who have a hard-to-treat CMV infection along with severe kidney disease or kidney failure. Researchers want to see how safe the drug maribavir is for these patients. No new treatments or procedures are given; the study only looks at existing data from routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants treated with maribavir for a refractory (with or without resistance) CMV infection and who have severe CKD or comorbid ESRD including participants on peritoneal dialysis or hemodialysis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults more than and equal to (≥) 18 years of age at index date. * Diagnosis of comorbid ESRD or comorbid severe CKD prior to the index date. * If ESRD (including participants on peritoneal dialysis or hemodialysis): participant diagnosed with ESRD confirmed by an estimated glomerular filtration rate (eGFR) less than (\<) 15 milliliters per minute per 1.73 square meters (mL/min/1.73m\^2). * If severe CKD: participant diagnosed with severe CKD confirmed by an eGFR of 15 to \<30 mL/min/1.73m\^2 at index. * Participant has undergone solid organ transplant (SOT) or hematopoietic stem cell transplantation (HSCT) before index date. * Participant was diagnosed with refractory (with or without resistance) CMV during the latest post-transplant period. * Participant initiated treatment with maribavir in routine practice within the eligibility period and received at least 1 dose of maribavir. * Informed consent provided (where required by local regulations) before data collection commences. Exclusion Criteria: There are no exclusion criteria for this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytomegalovirus (CMV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease cytomegalovirus infection end stage renal failure impaired renal function disease kidney disorder kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cytomegalovirus (CMV) Kidney disease Kidney failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    25 sites in 7 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AP-HP - Hopital Henri Mondor

    RECRUITING

    Créteil, Val-de-Marne, 94000, France

  • Azienda Ospedaliera Dei Colli - Ospedale Monaldi

    NOT_YET_RECRUITING

    Naples, 80131, Italy

  • C.H. Regional Reina Sofia - PPDS

    NOT_YET_RECRUITING

    Córdoba, 14004, Spain

  • CHU de Bordeaux - Hopital Pellegrin

    RECRUITING

    Bordeaux, Gironde, 33000, France

  • CHU de Brest - Hopital La Cavale Blanche

    RECRUITING

    Brest, Finistere, 29200, France

  • CHU de Grenoble Alpes - Hopital Michallon

    RECRUITING

    La Tronche, Isere, 38700, France

  • CHU de Montpellier - Hopital Lapeyronie

    RECRUITING

    Montpellier, Herault, 34090, France

  • Dorset County Hospital

    NOT_YET_RECRUITING

    Dorchester, Dorset, DT1 2JY, United Kingdom

  • Fondazione IRCCS Policlinico San Matteo

    NOT_YET_RECRUITING

    Pavia, 27100, Italy

  • Hopital Erasme - PPDS

    NOT_YET_RECRUITING

    Anderlecht, Brussels Capital, 1070, Belgium

  • Hospital Clinic de Barcelona

    NOT_YET_RECRUITING

    Barcelona, 8036, Spain

  • Hospital Regional Universitario de Malaga Hospital General

    RECRUITING

    Málaga, 29010, Spain

  • Hospital Universitario Cruces

    NOT_YET_RECRUITING

    Barakaldo, Vizcaya, 48903, Spain

  • Hospital Universitario Ramon y Cajal

    NOT_YET_RECRUITING

    Madrid, 28304, Spain

  • Hospital Universitario Vall d'Hebron - PPDS

    RECRUITING

    Barcelona, 8035, Spain

  • Hospital Universitario Virgen del Rocio - PPDS

    NOT_YET_RECRUITING

    Seville, 41013, Spain

  • Hospital Universitario de Bellvitge

    NOT_YET_RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 8907, Spain

  • King's College Hospital

    NOT_YET_RECRUITING

    London, SE5 9RS, United Kingdom

  • North Estonia Medical Centre Foundation

    RECRUITING

    Tallinn, Harju, 13419, Estonia

  • Queen Elizabeth Hospital Birmingham

    NOT_YET_RECRUITING

    Birmingham, B15 2GW, United Kingdom

  • Tartu University Hospital

    RECRUITING

    Tartu, 60535, Estonia

  • UZ Leuven - PPDS

    NOT_YET_RECRUITING

    Leuven, Vlaams Brabant, 3000, Belgium

  • Universitatsklinikum Leipzig

    NOT_YET_RECRUITING

    Leipzig, Saxony, 4103, Germany

  • Universitatsklinikum Wurzburg

    NOT_YET_RECRUITING

    Würzburg, Bavaria, 97080, Germany

  • Wrexham Maelor Hospital

    NOT_YET_RECRUITING

    Wrexham, LL13 7TD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.